Develops cancer drugs for uveal melanoma.
Jun 2026Revenue $234M/yrExpenses $451M/yr
No trendCash runway ≈ 7.3 years from Jun 2026
Figures by year
When will IDEAYA Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $234M and expenses $451M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $219M | $378M | −$159M |
| Dec 2024 | $7.00M | $334M | −$327M |
| Dec 2023 | $23.4M | $158M | −$134M |
| Dec 2022 | $50.9M | $113M | −$62.5M |
| Dec 2021 | $27.9M | $78.2M | −$50.3M |
| Dec 2020 | $19.5M | $54.9M | −$35.3M |
| Dec 2019 | $0.00 | $44.3M | −$44.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.